Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,767 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term safety of vedolizumab for inflammatory bowel disease.
Loftus EV Jr, Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, Danese S, D'Haens G, Rubin DT, Shafran I, Parfionovas A, Rogers R, Lirio RA, Vermeire S. Loftus EV Jr, et al. Among authors: rogers r. Aliment Pharmacol Ther. 2020 Oct;52(8):1353-1365. doi: 10.1111/apt.16060. Epub 2020 Sep 2. Aliment Pharmacol Ther. 2020. PMID: 32876349 Free PMC article. Clinical Trial.
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Sands BE, et al. Among authors: rogers r. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).
Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Danese S, Rogers R, Bornstein JD, Chen J, Schreiber S, Sands BE, Lirio RA. Peyrin-Biroulet L, et al. Among authors: rogers r. Gastroenterology. 2021 Oct;161(4):1156-1167.e3. doi: 10.1053/j.gastro.2021.06.015. Epub 2021 Jun 16. Gastroenterology. 2021. PMID: 34144047 Free article. Clinical Trial.
The Dermatologic Oral Examination: Navigating the Oral Dermatoses Map.
Klein PA, Aristizabal MA, Janovska M, Bruce AJ, Bodiford KJ, Rogers RS 3rd. Klein PA, et al. Among authors: rogers rs 3rd. J Am Acad Dermatol. 2025 Jan 9:S0190-9622(25)00038-6. doi: 10.1016/j.jaad.2024.10.125. Online ahead of print. J Am Acad Dermatol. 2025. PMID: 39798607 Review.
Patient Perceptions of Pessaries for Treatment of Pelvic Organ Prolapse.
Roberts BL, Marici L, Villafuerte E, Jacobs BE, Wolff GF, Rogers RG, Dahl JA, Deverdis EC. Roberts BL, et al. Among authors: rogers rg. Urogynecology (Phila). 2024 Dec 31. doi: 10.1097/SPV.0000000000001630. Online ahead of print. Urogynecology (Phila). 2024. PMID: 39787565
The Pelvic Floor Disorders Network: Evolution Over Two Decades of Female Pelvic Floor Research.
Richter HE, Visco A, Brubaker L, Sung V, Nygaard I, Arya L, Menefee S, Zyczynski HM, Schaffer J, Rogers RG, Kenton K, Paraiso MFR, Fine P, Mazloomdoost D, Gantz MG. Richter HE, et al. Among authors: rogers rg. Urogynecology (Phila). 2024 Oct 1;30(10):854-869. doi: 10.1097/SPV.0000000000001571. Urogynecology (Phila). 2024. PMID: 39752613 Review.
Ergogenic and Sympathomimetic Effects of Yohimbine: A Review.
Porrill SL, Rogers RR, Ballmann CG. Porrill SL, et al. Among authors: rogers rr. Neurol Int. 2024 Dec 12;16(6):1837-1848. doi: 10.3390/neurolint16060131. Neurol Int. 2024. PMID: 39728757 Free PMC article. Review.
2,767 results